An evaluation of the healthcare costs of metastatic breast cancer: A retrospective matched cohort study

Keyphrases

• Metastatic Breast Cancer 100%
• Matched Cohort Study 100%
• Health Care Costs 100%
• Breast Cancer 90%
• Cancer-free 60%
• Cost Ratio 20%
• Healthcare Utilization 20%
• Outpatient Cost 20%
• Economic Burden 20%
• Taiwan 10%
• National Health Insurance Research Database (NHIRD) 10%
• Cancer-related 10%
• Breast Cancer Patients 10%
• Generalized Linear Model 10%
• Targeted Therapy 10%
• Age Groups 10%
• Health Economics 10%
• Economic Evaluation 10%
• Human Epidermal Growth Factor Receptor 2 (HER2) 10%
• Emergency Room 10%
• Charlson Comorbidity Index 10%
• Retrospective Analysis 10%
• Residential Area 10%
• Free Group 10%
• Claims Database 10%
• Medical Resource Allocation 10%
• Taiwan Cancer Registry 10%
• Breast Cancer Recurrence 10%
• Cancer Healthcare 10%
• Endocrine Therapy 10%

Nursing and Health Professions

• Cohort Analysis 100%
• Health Care Cost 100%
• Metastatic Breast Cancer 100%
• Breast Cancer 81%
• Outpatient 18%
• Health Care Utilization 18%
• National Health Insurance 9%
• Resource Allocation 9%
• Emergency Ward 9%
• Charlson Comorbidity Index 9%
• Hormonal Therapy 9%
• Cancer Registry 9%
• Economic Evaluation 9%
• Health Care Planning 9%
• Gamma Urogastrone 9%
• Epidermal Growth Factor Receptor 2 9%

Pharmacology, Toxicology and Pharmaceutical Science

• Cohort Study 100%
• Metastatic Breast Cancer 100%
• Breast Cancer 81%
• Epidermal Growth Factor Receptor 2 9%
• Gamma Urogastrone 9%
• Endocrine Therapy 9%
• Cancer Registry 9%
• Comorbidity 9%